title: Age-specific occurrence of HPV16- and HPV18-related cervical cancer.
abstract: The age-specific occurrence of cervical cancer related to human papillomavirus (HPV) genotypes HPV16 and HPV18, the two targeted by current HPV vaccines, is not well described. We therefore used data from two large, tissue-based HPV genotyping studies of cervical cancer, one conducted in New Mexico (n = 744) and an International study restricted to cancers (n = 1,729) from Europe, North America, and Australia to represent those regions with widely available cervical cancer screening facilities. HPV results were categorized as HPV16- or HPV18-positive (HPV16/18) versus other HPV genotype. We observed a decreasing proportion of HPV16/18-positive cancers with increasing age in the International study (Ptrend < 0.001) and New Mexico study (Ptrend < 0.001). There was no heterogeneity in the relationship between age of diagnosis and the proportion of HPV16/18-positive cancers between studies (P = 0.8). Combining results from the two studies (n = 2,473), the percentages of HPV16/18-positive cases were 77.0% [95% confidence interval (CI): 75.1%-78.9%] for women less than 65 years old and 62.7% [95% confidence interval (CI): 58.4%-66.9%] for women aged 65 and older (P < 0.001). In women who are under the age of 25 and have been vaccinated before becoming sexually active, the cervical cancer incidence is expected to be approximately 3.5 per million by 2020. HPV vaccination against HPV16/18 may have a greater impact on cervical cancers in women under 65 than in women aged 65 and older. These data will inform the age-specific impact of HPV vaccination and its integration with cervical cancer screening activities.
authors: IDIBELL, Institut Catalàd'Oncologia-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.|CIBER en Epidemiología y Salud Pública, Barcelona, Spain.
authors: Silvia
authors: S
authors: de Sanjose
authors: University of New Mexico Health Sciences Center, Department of Pathology and Department of Obstetrics and Gynecology, House of Prevention Epidemiology (HOPE), Albuquerque, NM, USA.
authors: Cosette M
authors: CM
authors: Wheeler
authors: DDL Diagnostic Laboratory, Voorburg, Netherlands.
authors: Wim G V
authors: WGV
authors: Quint
authors: University of New Mexico Health Sciences Center, Department of Pathology and Department of Obstetrics and Gynecology, House of Prevention Epidemiology (HOPE), Albuquerque, NM, USA.
authors: William C
authors: WC
authors: Hunt
authors: University of New Mexico Health Sciences Center, Department of Pathology and Department of Obstetrics and Gynecology, House of Prevention Epidemiology (HOPE), Albuquerque, NM, USA.
authors: Nancy E
authors: NE
authors: Joste
authors: IDIBELL, Institut Catalàd'Oncologia-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.|CIBER en Epidemiología y Salud Pública, Barcelona, Spain.
authors: Laia
authors: L
authors: Alemany
authors: IDIBELL, Institut Catalàd'Oncologia-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.|CIBER en Epidemiología y Salud Pública, Barcelona, Spain.
authors: F Xavier
authors: FX
authors: Bosch
authors: Division of Clinical and Epidemiological Research, Department of Obstetrics & Gynecology, Duke University.
authors: Evan R
authors: ER
authors: Myers
authors: Global Cancer Initiative, Chestertown, MD, USA.
authors: Philip E
authors: PE
authors: Castle
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D003430:Cross-Sectional Studies; D005260:Female; D052162:Human papillomavirus 16 / Q000302:isolation & purification*; D052161:Human papillomavirus 18 / Q000302:isolation & purification*; D006801:Humans; D008875:Middle Aged; D009516:New Mexico / Q000453:epidemiology; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000821:virology*; D012189:Retrospective Studies; D018426:SEER Program; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000821:virology*; D055815:Young Adult
references: J Natl Cancer Inst. 2009 Apr 1;101(7):475-87
references: 19318628
references: Lancet. 2009 Jul 25;374(9686):301-14
references: 19586656
references: N Engl J Med. 2007 May 10;356(19):1928-43
references: 17494926
references: J Low Genit Tract Dis. 2010 Jul;14(3):238-340; author reply 240
references: 20592562
references: MMWR Morb Mortal Wkly Rep. 2011 Aug 26;60(33):1117-23
references: 21866084
references: BMJ. 2008 Sep 18;337:a1284
references: 18801868
references: CMAJ. 2013 Jan 8;185(1):35-45
references: 23297138
references: Lancet Oncol. 2010 Nov;11(11):1048-56
references: 20952254
references: BMJ. 2010 Jul 20;341:c3493
references: 20647284
references: Adv Data. 2005 Sep 15;(362):1-55
references: 16250464
references: Int J Cancer. 2011 Dec 1;129(11):2632-42
references: 21491420
references: N Engl J Med. 2007 May 10;356(19):1915-27
references: 17494925
references: Vaccine. 2009 Sep 18;27(41):5612-9
references: 19647066
references: CA Cancer J Clin. 2012 May-Jun;62(3):147-72
references: 22422631
references: J Infect Dis. 2009 Apr 1;199(7):936-44
references: 19236277
references: Eur J Cancer. 2009 Oct;45(15):2685-708
references: 19744852
references: Ann Oncol. 2010 Mar;21(3):448-458
references: 20176693
references: Hum Vaccin Immunother. 2012 Mar;8(3):390-7
references: 22327492
references: BMJ. 2009 Jul 28;339:b2968
references: 19638651
references: Obstet Gynecol. 2012 Nov;120(5):1117-23
references: 23090530
references: JAMA. 2007 Aug 15;298(7):743-53
references: 17699008
references: Lancet. 2009 Dec 12;374(9706):1975-85
references: 19962185